Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lemtrada shows 'durable remission' in MS extension study

This article was originally published in Scrip

Executive Summary

Interim data from an extension study for Genzyme's once-yearly multiple sclerosis therapy Lemtrada (alemtuzumab) show that the biologic continued to produce strong efficacy and more than 80% of patients did not need an additional injection during the first year of a three-year extension study following Sanofi's two-year Phase III clinical trials.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC020807

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel